KCM
HAE icon

Kingdon Capital Management’s Haemonetics HAE Stock Holding History

Kingdon Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100,000
Closed -$7.06M – 87
2021
Q3 		$7.06M Buy
+100,000
New +$6.31M 0.86% 36

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kingdon Capital Management's HAE Position: Q4 2023 in Review

Kingdon Capital Management sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 111,100 shares — an estimated $9.95M sold.

Kingdon Capital Management first reported a position in HAE in Q3 2021 and held it in 5 quarters. The position peaked at $9.95M in Q3 2023. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

  • Kingdon Capital Management reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
  • Kingdon Capital Management sold 111,100 Haemonetics shares in Q4 2023, an estimated $9.95M.
  • Kingdon Capital Management first reported a position in Haemonetics in Q3 2021 and held it in 5 quarters.
  • Kingdon Capital Management's Haemonetics position peaked at $9.95M in Q3 2023.
  • 295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Kingdon Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.